Trump signs FDA Reauthorization Act of 2017 into law

13:37 EDT 21 Aug 2017 | Healio

President Donald J. Trump recently signed the FDA Reauthorization Act of 2017 into law. The FDA Reauthorization Act of 2017 (H.R. 2430) reauthorizes the user fee programs for prescription drugs, medical devices, generic drugs and biosimilars, and amends FDA authorities and activities related to medical products. The user fees, which are paid by manufacturers of drugs and medical devices, account for $8 billion to $9 billion during a period of 5 years. The law includes the Generic Drug User Fee Amendments, the Biosimilar User Fee Act, the Prescription Drug User Fee Act and the Medical Device User Fee Amendments, which must be reauthorized by Sept. 30.

Original Article: Trump signs FDA Reauthorization Act of 2017 into law


More From BioPortfolio on "Trump signs FDA Reauthorization Act of 2017 into law"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...